drugset

drugset / Trial / NCT01824199

CYP2C19 Genotype Predictor of Gastric Acid Suppression

NCT01824199 ↗

Phase 0 Withdrawn Mayo Clinic

NaSingle-groupOpen-labelTreatment

Summary

If CYP2C19 genotype can predict the efficacy of healing erosive esophagitis and gastric acid secretion in patients taking once a day omeprazole.

Timeline

Start: 2013-03
Primary completion: 2016-11
Completion: 2016-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Omeprazole	Other / unclassified	40 mg	Oral

Indications